Considering the function of PELP1 in the promotion of chemotherapy resistance, future research is needed to assess the efficacy of combining SMIP34 with standard-of-care therapies for HCC, such as sorafenib. The gene discussed is PELP1; the disease is hepatocellular carcinoma.